ArticleScientific reports2026
In vitro and in vivo evaluation of oleuropein loaded hyalurosomes for diabetic foot ulcer healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers (DFUs) are among the most severe and challenging complications associated with diabetes mellitus, primarily due to chronic inflammation, oxidative stress, and impaired tissue regeneration. To develop and evaluate oleuropein-loaded hyalurosomes (OLE-HLs) as a unique topical nanocarrier system for wound healing using an experimental diabetic rat model. OLE-HLs were synthesized using a modified thin-film hydration method, and the nano-formulation was characterized by measuring the size and potential, followed by TEM, encapsulation efficiency, FTIR, in vitro release studies, and cell cytotoxicity assay. The wound-healing efficacy was evaluated in vitro, using scratch assay and in vivo, via studying the wound closure rate, oxidative stress markers, pro-inflammatory cytokines, TGFβ1 gene expression, and histopathological alterations, complemented by immunohistochemical analysis. OLE-HLs exhibited a mean particle size of 254.64 ± 9.84 nm, a zeta potential of - 25.12 ± 2.18 mV, and an encapsulation efficiency of 89.61 ± 1.82%, while TEM revealed spherical, uniformly sized, and well-dispersed vesicles, confirming stability and homogeneity. FTIR analysis verified successful oleuropein encapsulation and compatibility within the hyalurosomal system. The formulation displayed a biphasic release profile, with 26.47 ± 0.86% released in the first hour and 76.72 ± 2.45% within 24 h. Cytotoxicity assays showed enhanced bioactivity (IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.